Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 623-629

  Mukherjee, Biswajit ^a,b   Mayer, Doris ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

EGFR ubiquitination; ERK1 2; Interaction of androgen receptor and EGF receptor; MAP kinase; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUTAMIDE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SYNAPTOPHYSIN; AR PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REPORTER GENE; SIGNAL TRANSDUCTION; UBIQUITINATION; DRUG EFFECT; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANDROGENS; BLOTTING, WESTERN; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOPRECIPITATION; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSFECTION; UBIQUITINATION;

EID: 54849185800     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000048     Document Type: Article

References (47)

1. Grönberg H: Prostate cancer epidemiology. Lancet 361: 859-864, 2003.
2. Denmeade SR, Lin XS and Isaacs JT: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265, 1996.
3. Blok LJ, De Ruiter PE and Brinkmann AO: Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 37: 3850-3857, 1998.
4. Edwards J and Bartlett JMS: The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. part 1: modifications to the androgen receptor. BJU Int 95: 1320-1326, 2005.
5. Culig Z, Klocker H, Bartsch G and Hobisch A: Androgen receptors in prostate cancer. Endocr Relat Cancer 9: 155-170, 2002.
6. Di Loreto G, Tortora G and D'Armiento FP: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444, 2002.
7. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ and Thereadgill DW: Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99: 1521-1526, 2002.
8. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K and Stetler-Stevenson WG: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93: 1375-1384, 2001.
9. Kim HG, Kassis J, Souto JC, Turner T and Wells A: EGF receptor signalling in prostate morphogenesis and tumorigenesis. Histol Histopathol 14: 1175-1182, 1999.
10. Gschwind A, Fischer OM and Ullrich A: The discovery of the receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370, 2004.
11. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp, HS and Whang YE: Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65: 3404-3409, 2005.
12. Kharait S, Dhir R, Lauffenburger D and Wells A: Protein kinase Cδ signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 343: 848-856, 2006.
13. Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK and Veldhuizen PJV: Growth factors involved in prostate carcinogenesis. Front Biosci 10: 1335-1367, 2005.
14. Tyagi A, Agarwal R and Agarwal C: Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 22: 1302-1316, 2003.
15. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
16. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C and Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780-2785, 1991.
17. Saga K and Jimbow K: Immunohistochemical localization of activated EGF receptor in human eccrine and apocrine sweat glands. J Histochem Cytochem 49: 597-601, 2001.
18. Sheikh SSE, Domin J, Abel P, Stamp G and Lalani E: Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6: 846-853, 2004.
19. Shimada K, Nakamura M, Ishida E, Kishi M and Konishi N: Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24: 1067-1075, 2003.
20. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999.
21. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE and Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20: 1981-1989, 2001.
22. Davoodpour P and Landstrom M: 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J Biol Chem 280: 14773-14779, 2005.
23. Ricote M, Garcia-Tunon I, Fraile B, Fernandez C, Alter P, Paniagua R and Royuela M: P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis 11: 1169-1975, 2006.
24. Shimada K, Nakamura M, Ishida E and Konishi N: Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol Histopathol 21: 415-422, 2006.
25. Gravina GL, Festuccia C, Angelucci A, Poletti A, Capuano D, Vicentini C, Motta M and Bologna M: Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int J Oncol 25: 97-104, 2004.
26. Schmitt M, Klinga K, Schnarr B, Morfin R and Mayer D: Dehydroepiandrosterone stimulates proliferation and gene expression in breast cancer cells after conversion to estradiol. Mol Cell Endocrinol 173: 1-13, 2001.
27. Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G and Mayer D: Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor-α and is involved in the regulation of receptor activity. J Biol Chem 290: 33006-33014, 2005.
28. Fan M, Nakshatri H and Nephew KP: Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation. Mol Endrocrinol 18: 2603-2615, 2004.
29. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
30. Wilkinson MG and Millar JB: SAPKs and transcription factors do the nucleocytoplasmic tango. Genes Dev 12: 1391-1397, 1998.
31. Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinases in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403, 2003.
32. Yeh, S, Lin HK, Kang HY, Thin, TH, Lin MF and Chang C; From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target gene through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96: 5458-5463, 1999.
33. Tanka Y, Gavrielides MV, Mitsuuchi Y, Fujii T and Kazanietz MG: Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathways. J Biol Chem 278: 33753-33762, 2003.
34. Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME and Nicholson RI: Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. Prostate 49: 38-47, 2001.
35. Watson H, Franks S and Bonney RC: Regulation of epidermal growth factor receptor by androgens in human endometrial cells in culture. Hum Reprod 13: 2585-2591, 1998.
36. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH and Lin FF: Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 273: 5939-5947, 1998.
37. Zelivianski S, Larson C, Seberger J, Taylor R and Lin MF: Expression of human prostatic acid phosphatase gene is regulated by upstream negative and positive elements. Biochim Biophys Acta 1491: 123-132, 2000.
38. Krongard A, Wilson CM, Wilson JD, Allman DR and McPhaul MJ: Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 76: 79-88, 1991.
39. Wolf DA, Herzinger T, Hermeking H, Blaschke D and Horz W: Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol Endocrinol 7: 924-936, 1993.
40. Kemppainen JA, Lane MV, Sar M and Wilson EM: Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation: specificity for steroids and antihormones. J Biol Chem 267: 968-974, 1992.
41. Zhou ZX, Lane MV, Kemppainen JA, French FS and Wilson EM: Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9: 209-219, 1995.
42. Yeap BB, Roman GK and Leedman PJ: Differential post-transcriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 140: 3282-3291, 2006.
43. Quarmby VE, Yarbrough WG, Lubhan DB, French FS and Wilson EM: Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol 4: 22-29, 1990.
44. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE and Madshus IH: Ubiquitination and preteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156: 843-854, 2002.
45. Dikic I: Mechanisms controlling EGF receptor endocytosis and degradation. Biochem Soc Trans 31: 1178-1181, 2003.
46. Kanz Z, Pirskanen A, Janne OA and Palvimo JJ: Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277: 48366-48371, 2002.
47. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL and Chang C: Proteasome activity is required for androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277: 36570-36576, 2006.